Cargando…

Ocular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsification

OBJECTIVE: To evaluate the effect of adjunctive intravitreal triamcinolone (IVTA) on intraocular pressure (IOP) in the setting of combined vitrectomy with phacoemulsification. DESIGN: Retrospective case series. PARTICIPANTS: One hundred thirty-one consecutive eyes undergoing nonemergent vitrectomy w...

Descripción completa

Detalles Bibliográficos
Autores principales: Parke, D Wilkin, Sisk, Robert A, Houston, Samuel K, Murray, Timothy G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392914/
https://www.ncbi.nlm.nih.gov/pubmed/22791974
http://dx.doi.org/10.2147/OPTH.S32934
_version_ 1782237667496296448
author Parke, D Wilkin
Sisk, Robert A
Houston, Samuel K
Murray, Timothy G
author_facet Parke, D Wilkin
Sisk, Robert A
Houston, Samuel K
Murray, Timothy G
author_sort Parke, D Wilkin
collection PubMed
description OBJECTIVE: To evaluate the effect of adjunctive intravitreal triamcinolone (IVTA) on intraocular pressure (IOP) in the setting of combined vitrectomy with phacoemulsification. DESIGN: Retrospective case series. PARTICIPANTS: One hundred thirty-one consecutive eyes undergoing nonemergent vitrectomy with phacoemulsification and IVTA were reviewed and included in the analysis. All 131 eyes received 4 mg IVTA at the end of surgery. METHODS: Pre-and postoperative IOP, use of pressure-lowering medications, and rate of glaucoma surgery were analyzed. Pre-operative risk factors were analyzed. MAIN OUTCOME MEASURES: IOP, glaucoma medications, or glaucoma surgery. RESULTS: Secondary ocular hypertension (defined as IOP ≥ 25 mmHg) was found in 28 eyes (21%), the majority during postoperative day 1 only. Twelve eyes (9%) had an elevated IOP measurement noted at a visit after the first postoperative day. Five (4%) had an IOP rise of ≥10 mmHg over baseline at any time after postoperative day 1. Six (5%) required glaucoma medications. One eye required a glaucoma drainage implant for diabetic neovascular angle closure glaucoma, and one eye required enucleation for intractable neovascular glaucoma due to radiation retinopathy. Elevated postoperative IOP was statistically associated with higher baseline IOP and presence of preoperative glaucoma. CONCLUSIONS: Therapeutic intravitreal triamcinolone with combined vitrectomy and phacoemulsification causes infrequent and usually mild secondary ocular hypertension. Secondary ocular hypertension is associated with preoperative glaucoma and high IOP.
format Online
Article
Text
id pubmed-3392914
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-33929142012-07-12 Ocular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsification Parke, D Wilkin Sisk, Robert A Houston, Samuel K Murray, Timothy G Clin Ophthalmol Case Series OBJECTIVE: To evaluate the effect of adjunctive intravitreal triamcinolone (IVTA) on intraocular pressure (IOP) in the setting of combined vitrectomy with phacoemulsification. DESIGN: Retrospective case series. PARTICIPANTS: One hundred thirty-one consecutive eyes undergoing nonemergent vitrectomy with phacoemulsification and IVTA were reviewed and included in the analysis. All 131 eyes received 4 mg IVTA at the end of surgery. METHODS: Pre-and postoperative IOP, use of pressure-lowering medications, and rate of glaucoma surgery were analyzed. Pre-operative risk factors were analyzed. MAIN OUTCOME MEASURES: IOP, glaucoma medications, or glaucoma surgery. RESULTS: Secondary ocular hypertension (defined as IOP ≥ 25 mmHg) was found in 28 eyes (21%), the majority during postoperative day 1 only. Twelve eyes (9%) had an elevated IOP measurement noted at a visit after the first postoperative day. Five (4%) had an IOP rise of ≥10 mmHg over baseline at any time after postoperative day 1. Six (5%) required glaucoma medications. One eye required a glaucoma drainage implant for diabetic neovascular angle closure glaucoma, and one eye required enucleation for intractable neovascular glaucoma due to radiation retinopathy. Elevated postoperative IOP was statistically associated with higher baseline IOP and presence of preoperative glaucoma. CONCLUSIONS: Therapeutic intravitreal triamcinolone with combined vitrectomy and phacoemulsification causes infrequent and usually mild secondary ocular hypertension. Secondary ocular hypertension is associated with preoperative glaucoma and high IOP. Dove Medical Press 2012 2012-06-18 /pmc/articles/PMC3392914/ /pubmed/22791974 http://dx.doi.org/10.2147/OPTH.S32934 Text en © 2012 Parke III et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Case Series
Parke, D Wilkin
Sisk, Robert A
Houston, Samuel K
Murray, Timothy G
Ocular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsification
title Ocular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsification
title_full Ocular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsification
title_fullStr Ocular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsification
title_full_unstemmed Ocular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsification
title_short Ocular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsification
title_sort ocular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsification
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392914/
https://www.ncbi.nlm.nih.gov/pubmed/22791974
http://dx.doi.org/10.2147/OPTH.S32934
work_keys_str_mv AT parkedwilkin ocularhypertensionafterintravitrealtriamcinolonewithvitrectomyandphacoemulsification
AT siskroberta ocularhypertensionafterintravitrealtriamcinolonewithvitrectomyandphacoemulsification
AT houstonsamuelk ocularhypertensionafterintravitrealtriamcinolonewithvitrectomyandphacoemulsification
AT murraytimothyg ocularhypertensionafterintravitrealtriamcinolonewithvitrectomyandphacoemulsification